BACKGROUND: The current study was performed to evaluate two regimens of treatment and to describe clinical and epidemiologic characteristics in @entity1 with @entity995 . METHODS: Eighty-three @entity1 with @entity995 according to @entity5 Group (CCG) classification were admitted to the Pediatric Department of the A. C. Camargo between 1987-2000. The age, gender, race, lag time, first clinical presentation, staging, laterality, and treatment regimen were analyzed. Treatment was comprised of @entity900 , @entity2663 , @entity1891 , @entity632 , and @entity786 during the first treatment period (1987-1991) or @entity900 and @entity2663 with alternating courses of @entity1260 and @entity2879 during the second treatment period (1992-2000). RESULTS: The mean age of the @entity1 was 32.9 months (range, 2-145 months). The mean lag time was 10.5 months. Forty-three @entity1 were treated in the first period and 40 @entity1 were treated in the second period. Locally advanced @entity5 (Class I-III) were present in 83.1% of the @entity1 . There was a positive correlation between lag time and age for @entity5 (correlation coefficient [r] = 0.35; P = 0.006), whereas the correlation was negative for @entity5 (r = -0.12; P = 0.63). The 5-year overall survival was 55.1% in the first treatment period and 59.4% in the second treatment period (P = 0.69). No significant differences with regard to survival rates were noted for @entity5 between the two treatment periods (44.6 noted for @entity5 vs. 59.1 noted for @entity5 ). CONCLUSIONS: In the current study, the addition of @entity1260 and @entity2879 to a treatment regimen comprised of @entity900 , @entity2663 , @entity1891 , @entity632 , and @entity786 did not appear to improve the survival of @entity1 with @entity995 . @entity1 with dissemination to the central nervous system or @entity3 remain incurable and die of progressive disease, despite the aggressive treatment. A multicenter trial should be considered to evaluate the best strategy for these situations.

XXXX : a 13-year experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity2663 :: ('MESH:D013713', 'Chemical') :: ['teniposide'] @entity5 :: ('MESH:D009369', 'Disease') :: ['bilateral tumors', 'unilateral tumors', 'Childrens Cancer', 'tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity995 :: ('MESH:D012175', 'Disease') :: ['extraocular retinoblastoma']
@entity995 :: (MESH:D012175,Disease) :: ['Extraocular retinoblastoma']
